Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)
Status:
Terminated
Trial end date:
2020-04-30
Target enrollment:
Participant gender:
Summary
In vitro studies revealed that lopinavir/ritonavir and hydroxychloroquine have antiviral
activity against Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there
is no clinical studies on the reduction of viral load in patients with COVID-19. This study
investigate whether lopinavir/ritonavir or hydroxychloroquine reduces viral load from
respiratory specimen in patients with mild COVID-19.